Is Mangoceuticals Inc (MGRX) Stock a Good Investment?
Learn more about Mangoceuticals Inc's (MGRX) stock grades for Growth and determine whether this Healthcare Facilities & Services stock meets your investment needs.Jenna Brashear
Stock Evaluator: Mangoceuticals, Inc. (MGRX)
Mangoceuticals, Inc. MGRX
$0.56
0.26
89.75%
July 31, 2026 4:00:00 PM
EST
Volume: 510,791,193
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Consumer Staples | Consumer Staples Distribution & Retail |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Mangoceuticals, Inc. engages in the development, marketing, and sale of various men’s wellness products and services through a telemedicine platform in the United States. The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand. It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations. In addition, the company markets and sells its products online through its website www.MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
Commentary & Analysis
Financial Summary
| Share Statistics | MGRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $9.6 | $5,620.1 | 6% |
|
| Shares Out (Mil) | 16.5 | 101.6 | 27% |
|
| Institutional Ownership | 23.5% | 50.0% | 11% |
|
| Float (Mil) | 13.4 | 191.6 | 23% |
|
| Beta | 2.27 | 0.63 | 95% |
|
| Avg Daily Volume (000s) | 59,254 | 150 | 100% |
|
| Price Change (52-week) |
(66.8%) | 80.3% | 10% |
|
| Growth | MGRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | na | 12.3% | na |
|
| EPS (5yr) | na | 14.1% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (16.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | MGRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $0 | $9,161 | 1% |
|
| Net Income (TTM) (Mil) | ($19) | $209 | 24% |
|
| EPS (TTM) | ($1.563) | $0.600 | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($5) | $519 | 25% |
|
| Net Cash Flow (TTM) (Mil) | na | $6 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $966 | 12% |
|
| Enterprise Value (Q1) (Mil) | $7 | $6,174 | 6% |
|
| Valuation | MGRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.71 | 3.64 | 14% |
|
| P/E | na | 22.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | MGRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 52.4% | 24.4% | 65% |
|
| Net Margin | na | 2.1% | na |
|
| ROA | (106.1%) | 4.1% | 5% |
|
| ROE | (113.9%) | 12.3% | 8% |
|
| Liabilities to Assets | 6.7% | 69.4% | 3% |
|
| F-Score | 2 | 5 | 7% |
|
Mangoceuticals, Inc. did not pass any screens on 7/31/2026.
